Serplulimab Plus Chemotherapy vs Chemotherapy for Treatment of US and Chinese Patients with Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analysis to Inform Drug Pricing

被引：0
|
作者：
Taihang Shao
Mingye Zhao
Leyi Liang
Wenxi Tang
机构：
[1] China Pharmaceutical University,Center for Pharmacoeconomics and Outcomes Research
[2] China Pharmaceutical University,Department of Public Affairs Management, School of International Pharmaceutical Business
来源：
BioDrugs | 2023年 / 37卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：421 / 432
页数：11
相关论文
共 50 条
  • [21] Is more better? Chemotherapy for patients with extensive-stage small-cell lung cancer
    Johnson, BE
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (04) : 254 - 255
  • [22] INTENSIVE WEEKLY CHEMOTHERAPY FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL-CELL LUNG-CANCER
    MURRAY, N
    SHAH, A
    OSOBA, D
    PAGE, R
    KARSAI, H
    GRAFTON, C
    GODDARD, K
    FAIREY, R
    VOSS, N
    JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (09) : 1632 - 1638
  • [23] First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
    Horn, L.
    Mansfield, A. S.
    Szczesna, A.
    Havel, L.
    Krzakowski, M.
    Hochmair, M. J.
    Huemer, F.
    Losonczy, G.
    Johnson, M. L.
    Nishio, M.
    Reck, M.
    Mok, T.
    Lam, S.
    Shames, D. S.
    Liu, J.
    Ding, B.
    Lopez-Chavez, A.
    Kabbinavar, F.
    Lin, W.
    Sandler, A.
    Liu, S. V.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (23): : 2220 - 2229
  • [24] Cost-effectiveness of serplulimab as first-line therapy for extensive-stage small cell lung cancer in China
    Xiang, Guiyuan
    Jiang, Tingting
    Gan, Lanlan
    Wu, Yuanlin
    Zhang, Ni
    Xing, Haiyan
    Su, Hui
    Li, Yanping
    Peng, Dan
    Ni, Rui
    Liu, Yao
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [25] First-line treatments for extensive-stage small-cell lung cancer with immune checkpoint inhibitors plus chemotherapy: a China-based cost-effectiveness analysis
    Yi, Lidan
    Zhou, Zhen
    Zeng, Xiaohui
    Tan, Chongqing
    Liu, Qiao
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [26] First-line Immuno-chemotherapy for extensive-stage small-cell lung cancer: A network meta-analysis and cost-effectiveness analysis
    Zhu, Youwen
    Liu, Kun
    Yang, Qiuping
    Zeng, Manting
    Peng, Libo
    FRONTIERS IN PUBLIC HEALTH, 2023, 11
  • [27] Phase 1 study of pembrolizumab plus chemotherapy in Japanese patients with extensive-stage small-cell lung cancer
    Nogami, Naoyuki
    Tokito, Takaaki
    Zenke, Yoshitaka
    Satouchi, Miyako
    Seto, Takashi
    Saka, Hideo
    Ohtani, Junko
    Han, Shirong
    Noguchi, Kazuo
    Nishio, Makoto
    INVESTIGATIONAL NEW DRUGS, 2024, 42 (01) : 136 - 144
  • [28] Phase 1 study of pembrolizumab plus chemotherapy in Japanese patients with extensive-stage small-cell lung cancer
    Naoyuki Nogami
    Takaaki Tokito
    Yoshitaka Zenke
    Miyako Satouchi
    Takashi Seto
    Hideo Saka
    Junko Ohtani
    Shirong Han
    Kazuo Noguchi
    Makoto Nishio
    Investigational New Drugs, 2024, 42 : 136 - 144
  • [29] First-Line Treatments for Extensive-Stage Small-Cell Lung Cancer With Immune Checkpoint Inhibitors Plus Chemotherapy: A Network Meta-Analysis and Cost-Effectiveness Analysis
    Kang, Shuo
    Wang, Xinchen
    Zhang, Yue
    Zhang, Boyuan
    Shang, Fangjian
    Guo, Wei
    FRONTIERS IN ONCOLOGY, 2022, 11
  • [30] Cost-effectiveness of benmelstobart and anlotinib plus chemotherapy as first-line therapy for extensive-stage small cell lung cancer in China
    Chunyan Yan
    Zhengxiong Li
    Jiayan Li
    Quan Zhao
    Wenxiu Cao
    Shuqing Li
    Ruigang Diao
    Scientific Reports, 15 (1)
12345